Related references
Note: Only part of the references are listed.BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
Mariana Villalobos-Ortiz et al.
CELL DEATH AND DIFFERENTIATION (2020)
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
Piers Blombery et al.
BLOOD (2020)
DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
Martijn Kerkhofs et al.
BIOMOLECULES (2020)
Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2
Mart Bittremieux et al.
CELL DEATH AND DIFFERENTIATION (2019)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Binu K. Sasi et al.
LEUKEMIA (2019)
Topoisomerase II inhibitors in AML: past, present, and future
Minas P. Economides et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Romain Guieze et al.
CANCER CELL (2019)
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Ryan M. Young et al.
IMMUNOLOGICAL REVIEWS (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
The rise of apoptosis: targeting apoptosis in hematologic malignancies
Rebecca Valentin et al.
BLOOD (2018)
Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling
Tamara Vervloessem et al.
CELL CALCIUM (2018)
Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones
Clark W. Distelhorst
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2018)
BH4-mimetics and -antagonists: an emerging class of Bcl-2 protein modulators for cancer therapy
Adrien Nougarède et al.
Oncotarget (2018)
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Joan Montero et al.
CELL DEATH AND DIFFERENTIATION (2018)
BCL-2 family proteins: changing partners in the dance towards death
Justin Kale et al.
CELL DEATH AND DIFFERENTIATION (2018)
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi et al.
NATURE COMMUNICATIONS (2017)
The flashlights on a distinct role of protein kinase Cδ: Phosphorylation of regulatory and catalytic domain upon oxidative stress in glioma cells
Matus Misuth et al.
CELLULAR SIGNALLING (2017)
BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
Kamil Bojarczuk et al.
BLOOD (2016)
Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding
Ting Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Bcl-2 proteins and calcium signaling: complexity beneath the surface
T. Vervliet et al.
ONCOGENE (2016)
Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation
Mu He et al.
PLOS ONE (2016)
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
Jiusheng Deng et al.
ONCOTARGET (2016)
Antagonizing Bcl-2's BH4 domain in cancer
Tamara Vervloessem et al.
AGING-US (2015)
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Bingshe Han et al.
CANCER CELL (2015)
ERK1/2 has an essential role in B cell receptor- and CD40-induced signaling in an in vitro model of germinal center B cell selection
Jemal Adem et al.
MOLECULAR IMMUNOLOGY (2015)
Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263
E. F. Greenberg et al.
CELL DEATH & DISEASE (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R. Lavik et al.
ONCOTARGET (2015)
Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity
Ivan Cherh Chiet Low et al.
BLOOD (2014)
Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells
Hong Liu et al.
AUTOPHAGY (2013)
Chronic lymphocytic leukemia: A tale of one or two signals?
Nicholas Chiorazzi et al.
CELL RESEARCH (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Inhibiting AKT Phosphorylation Employing Non-Cytotoxic Anthraquinones Ameliorates TH2 Mediated Allergic Airways Disease and Rhinovirus Exacerbation
Caio Cesar de Souza Alves et al.
PLOS ONE (2013)
IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2
H. Akl et al.
CELL DEATH & DISEASE (2013)
Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
Rhonda M. Perciavalle et al.
NATURE CELL BIOLOGY (2012)
Induction of Ca2+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction
Fei Zhong et al.
BLOOD (2011)
Akt-Dependent Glucose Metabolism Promotes Mcl-1 Synthesis to Maintain Cell Survival and Resistance to Bcl-2 Inhibition
Jonathan L. Coloff et al.
CANCER RESEARCH (2011)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Pablo G. Longo et al.
BLOOD (2008)
Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals
Yi-Ping Rong et al.
MOLECULAR CELL (2008)
Mimicking the BH3 domain to kill cancer cells
T. Ni Chonghaile et al.
ONCOGENE (2008)
mTORC1 promotes survival through translational control of Mcl-1
John R. Mills et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
U Maurer et al.
MOLECULAR CELL (2006)
miR-15 and miR-16 induce apoptosis by targeting BCL2
A Cimmino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells
A Petlickovski et al.
BLOOD (2005)
Share Paper
